denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Session: How Do We Calibrate Cellular Therapy for Lymphoma in 2023?
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Lymphomas, non-Hodgkin lymphoma, Bispecific Antibody Therapy, Non-Biological therapies, Clinical Research, health outcomes research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chemotherapy, Combination therapy, Checkpoint Inhibitor, drug development, Diseases, indolent lymphoma, real-world evidence, aggressive lymphoma, Therapies, Immunotherapy, Lymphoid Malignancies, Monoclonal Antibody Therapy, Natural Killer (NK) Cell Therapies
Session: How Do We Calibrate Cellular Therapy for Lymphoma in 2023?
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Lymphomas, non-Hodgkin lymphoma, Bispecific Antibody Therapy, Non-Biological therapies, Clinical Research, health outcomes research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chemotherapy, Combination therapy, Checkpoint Inhibitor, drug development, Diseases, indolent lymphoma, real-world evidence, aggressive lymphoma, Therapies, Immunotherapy, Lymphoid Malignancies, Monoclonal Antibody Therapy, Natural Killer (NK) Cell Therapies
Saturday, December 9, 2023, 9:30 AM-10:45 AM
Disclosures: Nastoupil: Gilead Sciences/Kite Pharma: Honoraria, Research Funding; AstraZeneca: Honoraria; Genentech, Inc., Genmab, Gilead/Kite, Janssen, Merck, Novartis, Takeda: Honoraria, Research Funding; Regeneron: Honoraria; Daiichi Sankyo: Honoraria, Research Funding; DeNovo: Honoraria; Caribou Biosciences: Honoraria, Research Funding; Bristol Myers Squibb/Celgene: Honoraria, Research Funding; ADC Therapeutics: Honoraria; AbbVie: Honoraria.
See more of: How Do We Calibrate Cellular Therapy for Lymphoma in 2023?
See more of: Education Program
See more of: Education Program